Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

被引：0
|
作者：
Thomas E. Stinchcombe
Mark A. Socinski
Christine M. Walko
Bert H. O’Neil
Frances A. Collichio
Anastasia Ivanova
Hua Mu
Michael J. Hawkins
Richard M. Goldberg
Celeste Lindley
E. Claire Dees
机构：
[1] University of North Carolina,Department of Hematology/Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center
[2] University of North Carolina,School of Pharmacy
[3] Lineberger Comprehensive Cancer Center,Department of Biostatics
[4] Abraxis BioScience,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2007年 / 60卷
关键词：
Dose-limiting toxicity; Maximum tolerated dose; Melanoma; Non-small-cell lung cancer; Small-cell lung cancer; Clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：759 / 766
页数：7
相关论文
共 50 条
  • [11] SPARC expression in head and neck cancer correlates with tumor response to nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane)
    Trieu, Vuong
    Damascelli, Bruno
    Soon-Shiong, Patrick
    Desai, Neil
    CANCER RESEARCH, 2006, 66 (08)
  • [12] Combined modality treatment with ABI-007, nanoparticle albumin-bound (nab) paclitaxel:: modification of radiation response in vivo
    Wiedenmann, N.
    Valdecanas, D.
    Hunter, N.
    Farrar, D.
    Milas, L.
    Mason, K.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2007, 183 : 97 - 97
  • [13] Phase I and pharmacokinetic study of ABI-007, a Cremophor®-free nanoparticle formulation of paclitaxel, administered weekly in Japanese patients with solid tumors.
    Ando, Masashi
    Yonemori, Kan
    Nakanao, Eriko
    Yunokawa, Mayu
    Kouno, Tsutomu
    Shimizu, Chikako
    Tamura, Enji
    Katsumata, Noriyuki
    Fujiwara, Yasuhiro
    Ooyane, Mamoru
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3455S - 3456S
  • [14] Albumin-Bound Paclitaxel, ABI-007 May Show Better Efficacy than Paclitaxel in Basal-Like Breast Cancers: Association Between Caveolin-1 Expression and ABI-007
    Kadri Altundag
    Nilufer Bulut
    Omer Dizdar
    Hakan Harputluoglu
    Breast Cancer Research and Treatment, 2006, 100 : 329 - 330
  • [15] Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: Association between caveolin-1 expression and ABI-007
    Altundag, Kadri
    Bulut, Nilufer
    Dizdar, Omer
    Harputluoglu, Hakan
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 329 - 330
  • [16] SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol
    Desai, N
    Trieu, V
    Yao, R
    Frankel, T
    Soon-Shiong, P
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S26 - S27
  • [17] Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
    Sparreboom, A
    Scripture, CD
    Trieu, V
    Williams, PJ
    De, TP
    Yang, A
    Beals, B
    Figg, WD
    Hawkins, M
    Desai, N
    CLINICAL CANCER RESEARCH, 2005, 11 (11) : 4136 - 4143
  • [18] Preliminary results of phase I trial of carboplatin (CP) in combination with ABI-007 administered weekly or every 3 weeks in patients (pts) with solid tumors.
    Stinchcombe, TE
    Dees, EC
    Walko, CM
    Lindley, C
    Collichio, FA
    Carey, LA
    Turner, JE
    Mu, H
    Socinski, MA
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S71 - S71
  • [19] Phase I and pharmacokinetic study of ABI-007, a Cremophor®-free nanoparticle formulation of paclitaxel, administered once every 3 weeks in Japanese patients with solid tumors.
    Mukohara, Toru
    Nakajima, Hikaru
    Nagai, Shunji
    Minami, Hironobu
    Yamamoto, Noboru
    Yamada, Kazuhiko
    Yamada, Yasuhide
    Tamura, Tomohide
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3456S - 3456S
  • [20] Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies
    Nyman, DW
    Campbell, KJ
    Hersh, E
    Long, K
    Richardson, K
    Trieu, V
    Desai, N
    Hawkins, MJ
    Von Hoff, DD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 7785 - 7793
12345